Positive results in recent animal study strongly support first-ever human investigation for DehydraTECH-liraglutide KELOWNA, ...

They rationed their remaining supplies, stretching the weekly injections to 10 days, two weeks, even three weeks. They ...

Lexaria Bioscience (LEXX) has released an update.Pick the best stocks and maximize your portfolio:Discover top-rated stocks from highly ranked ...

Hims & Hers Health, Inc. has shown significant improvement in key unit economics, positioning it among top-tier SaaS ...

The anorexiant market is expected to grow from USD 1,145 million in 2024 to USD 1,883 million by 2034, at a CAGR of 5.1%.

Ozempic and similar drugs have been linked to possibly helping diseases beyond diabetes and obesity. Are they miracle drugs?

Indian pharmaceutical companies, which benefited from sector tailwinds such as stable generic pricing and shortage-led ...

Studies suggest that semaglutide reduces heart attack and stroke and may curb addiction and more. Scientists reflect on the future of GLP-1 drugs beyond weight loss.

Scientists uncover how TRH neurons suppress hunger by inhibiting AgRP neurons, advancing our understanding of GLP-1-based ...

The darlings of the weight loss and diabetes spaces, GLP-1 receptor agonists have shown promise against Alzheimer’s in recent studies—with Phase III results expected next year from Novo Nordisk.

Lilly's rival Danish firm Novo Nordisk is also working to bring its obesity drug Wegovy (Semaglutide) to India soon, and ...